

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Chaoju Eye Care Holdings Limited

朝聚眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2219)

DISCLOSEABLE TRANSACTION SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCT

SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCT

In order to fully utilize the Group's idle funds and generate better returns, on June 10, 2026, Chaoju Eye Care (HK) Company Limited ("**Chaoju HK**") (an indirect wholly-owned subsidiary of the Company) subscribed for the Structured Deposit Product in the total principal amount of USD31.8 million offered by JPMorgan Chase Bank, N.A. ("**JPMorgan Chase Bank**").

The Subscription is funded by surplus cash of the Group and not by the proceeds from the Global Offering.

IMPLICATIONS UNDER THE LISTING RULES

As one or more of the applicable percentage ratios (as defined under the Listing Rules) exceed 5% but are less than 25%, the Subscription constitutes a discloseable transaction of the Company and is hence subject to the reporting and announcement requirements but are exempted from the circular and Shareholders' approval requirements under Chapter 14 of the Listing Rules.

SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCT

The Board announces that, in order to fully utilize the Group's idle funds and generate better returns, on June 10, 2026, Chaoju HK (an indirect wholly-owned subsidiary of the Company) subscribed for the Structured Deposit Product in the total principal amount of USD31.8 million offered by JPMorgan Chase Bank.

The Structured Deposit Product

Date of subscription:	June 10, 2026
Name of the structured deposit product:	USD STRUCTURED DEPOSIT LINKED TO 10Y CGB YIELD
Parties:	(a) Chaoju HK; and (b) JPMorgan Chase Bank
Principal amount of subscription:	USD31.8 million
Term of product:	From June 11, 2026 to June 11, 2027
Type of product:	The Structured Deposit Product is principal guaranteed but does not guarantee a fixed interest amount. The interest amount payable on the interest payment date is dependent on JPMorgan Chase Bank and the performance of the reference rate (i.e. the closing rate of the ChinaBond Government Bond Yield Curve produced by China Central Depository & Clearing Co., Ltd. to reflect the yield-to-maturity of onshore-traded RMB Treasury Coupon Bonds and Treasury Discount Bonds with a maturity of 10 years, expressed as a percentage).
Expected interest rate:	$3.95\% + 0.10\% \times N/M$

Where,

“N” means the number of calendar days during the period commencing on and including June 11, 2026, and ending on but excluding June 11, 2027 (the “**Interest Period**”) on which the reference rate is lower than 0.00%

“M” means the actual number of calendar days in such Interest Period.

If such rate does not appear, the rate shall be determined by JPMorgan Chase Bank in good faith and in a commercially reasonable manner

REASONS FOR AND BENEFITS OF THE SUBSCRIPTION

The Subscription is carried out by the Company for treasury management purpose in order to enhance the utilization of and maximize the return on the surplus cash received from its business operations. The Subscription is funded by surplus cash of the Group and not by the proceeds from the Global Offering.

The Group expects that the Structured Deposit Product will earn a better yield than current deposits generally offered by commercial banks in the PRC while at the same time offer flexibility to the Group in terms of treasury management. Further, the Group has implemented adequate and appropriate internal control procedures to ensure the Subscription would not affect the working capital or the operations of the Group, and that such investment would be closely monitored and conducted in accordance with the Group's treasury policy. As such, the Board is of the view that the terms of the Structured Deposit Product are fair and reasonable, and are on normal commercial terms and the Subscription is in the interests of the Company and the Shareholders as a whole.

INFORMATION ABOUT THE PARTIES

The Group

The Group is a leading ophthalmic medical service group in North China with a strong reputation nationwide. As of the date of this announcement, the Group operated a network of 32 ophthalmic hospitals and 32 optical centers spanning across 7 provinces, cities and autonomous regions in China. The ophthalmic hospitals are specialized in providing ophthalmic services and the optical centers provide a series of optical products and services to satisfy a wide array of requests from customers.

JPMorgan Chase Bank, N.A.

JPMorgan Chase Bank, N.A. (acting through its Hong Kong branch for the purpose of the structured deposit products) is part of JPMorgan Chase & Co. (NYSE: JPM), an American multinational financial services firm headquartered in New York City and incorporated in Delaware. It has operations worldwide, which offers investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management.

As of the date of this announcement and to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, JPMorgan Chase Bank and its respective ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Listing Rules).

IMPLICATIONS UNDER THE LISTING RULES

As one or more of the applicable percentage ratios (as defined under the Listing Rules) exceed 5% but are less than 25%, the Subscription constitutes a discloseable transaction of the Company and is hence subject to the reporting and announcement requirements but is exempted from the circular and Shareholders' approval requirements under Chapter 14 of the Listing Rules.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following words and expressions shall have the meaning ascribed to them below:

“Board”	the board of Directors
“China” or the “PRC”	the People’s Republic of China, but for the purpose of this announcement and for geographical reference only, references herein to “China” and the “PRC” do not apply to Hong Kong, Macau and Taiwan
“Company”	Chaoju Eye Care Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands on May 19, 2020
“Director(s)”	director(s) of the Company
“Global Offering”	the Hong Kong Public Offering and the International Offering (both as defined in the Prospectus)
“Group”	the Company together with its subsidiaries
“HK\$”	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Prospectus”	the prospectus of the Company published on June 24, 2021
“RMB”	the lawful currency of the PRC

“Share(s)”	ordinary share(s) in the share capital of the Company with nominal value of HK\$0.00025 each
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Structured Deposit Product”	the structured deposit product offered by JPMorgan Chase Bank and subscribed by the Group on June 10, 2026, the details of which are set out in this announcement
“Subscription”	subscription of the Structured Deposit Product
“%”	per cent

By order of the Board
Chaoju Eye Care Holdings Limited
ZHANG Bozhou
Chairman

Hong Kong, June 10, 2026

As of the date of this announcement, the board of directors of the Company comprises Mr. ZHANG Bozhou as the chairman and executive Director; Ms. ZHANG Xiaoli, Mr. ZHANG Junfeng and Mr. ZHANG Guangdi as executive Directors; Mr. Richard Chen MAO, Mr. LI Zhen and Ms. ZHANG Li as non-executive Directors; and Mr. HE Mingguang, Ms. GUO Hongyan, Mr. LI Jianbin and Mr. BAO Shan as independent non-executive Directors.

** The English translation of the Chinese names denoted in this announcement is for illustration purposes only. Should there be any inconsistencies, the Chinese name shall prevail.*